2197 Stock Overview
A biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Clover Biopharmaceuticals, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.28 |
| 52 Week High | HK$1.81 |
| 52 Week Low | HK$0.26 |
| Beta | 3.82 |
| 11 Month Change | -11.11% |
| 3 Month Change | -37.08% |
| 1 Year Change | -80.95% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.84% |
Recent News & Updates
Recent updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 05Shareholder Returns
| 2197 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 5.7% | 0.8% | -0.1% |
| 1Y | -81.0% | -28.6% | -3.2% |
Return vs Industry: 2197 underperformed the Hong Kong Biotechs industry which returned -28.6% over the past year.
Return vs Market: 2197 underperformed the Hong Kong Market which returned -3.2% over the past year.
Price Volatility
| 2197 volatility | |
|---|---|
| 2197 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.5% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2197's share price has been volatile over the past 3 months.
Volatility Over Time: 2197's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 387 | Joshua G. Liang | www.cloverbiopharma.com |
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment.
Clover Biopharmaceuticals, Ltd. Fundamentals Summary
| 2197 fundamental statistics | |
|---|---|
| Market cap | HK$356.69m |
| Earnings (TTM) | -HK$150.47m |
| Revenue (TTM) | HK$42.63m |
8.5x
P/S Ratio-2.4x
P/E RatioIs 2197 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2197 income statement (TTM) | |
|---|---|
| Revenue | CN¥39.26m |
| Cost of Revenue | CN¥1.71b |
| Gross Profit | -CN¥1.67b |
| Other Expenses | -CN¥1.53b |
| Earnings | -CN¥138.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -4,262.30% |
| Net Profit Margin | -352.92% |
| Debt/Equity Ratio | -42.0% |
How did 2197 perform over the long term?
See historical performance and comparison